Grand Pharma's FAP-Targeted Radiopharmaceutical GPN01530-2 Earns FDA Fast Track Designation for Solid Tumor Diagnosis
核心洞察
Grand Pharmaceutical's GPN01530-2 (搜索), a novel FAP-targeted radiopharmaceutical conjugate, received FDA Fast Track Designation for diagnosing solid tumors (搜索).
The agent targets fibroblast activation protein (搜索) (FAP), highly expressed in approximately 90% of epithelial tumor tissues but low or absent in normal tissues.
Investigator-initiated trial data showed GPN01530-2 (搜索) detected more lesions with higher tumor-to-background ratios compared to both 68Ga-FAPI-46 and 18F-FDG in 35 patients.
Grand Pharmaceutical Group Limited (搜索) (HKEX: 00512) announced that GPN01530-2 (搜索), a globally innovative radiopharmaceutical drug conjugate (RDC) independently developed by the Group for diagnosing solid tumors (搜索), has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation marks a significant regulatory milestone for the company's radiopharmaceutical oncology diagnostics portfolio and positions the candidate for an accelerated development and review pathway.
The FDA's Fast Track program is designed to expedite the review of new drugs intended to treat serious or life-threatening conditions for which there are no effective therapies and that demonstrate potential to address unmet medical needs. Candidates receiving FTD may qualify for more frequent interactions with the FDA, priority review if relevant criteria are met, and rolling review of their New Drug Applications, thereby accelerating development and market approval timelines. Previously, GPN01530-2 (搜索) had received FDA clearance to initiate Phase I/II clinical trials for diagnosing solid tumors (搜索).
Targeting FAP: A Novel Diagnostic Approach
GPN01530-2 (搜索) is a small-molecule RDC targeting fibroblast activation protein (搜索) (FAP), a key biomarker of cancer-associated fibroblasts (CAFs). FAP plays a critical role in extracellular matrix remodeling, regulation of tumor cell proliferation, and induction of tumor immune suppression — processes that promote tumor growth and invasion. Studies indicate that FAP is either absent or expressed at low levels in normal tissues but is highly expressed in approximately 90% of epithelial tumor tissues and CAFs within various tumor microenvironments.
The current standard-of-care PET/CT imaging agent, fluorine-18 fluorodeoxyglucose (18F-FDG), assesses disease based on glucose metabolism levels in lesions; however, its sensitivity is relatively low, ranging from 40% to 68%, limiting its utility in early tumor detection. In contrast, FAP-targeted imaging agents demonstrate broad applicability across solid tumors (搜索) and high sensitivity, positioning them as one of the most promising targets in radiopharmaceutical research.
Preclinical and Clinical Evidence
Grand Pharma's proprietary GPN01530-2 (搜索) features an optimized FAP ligand structure that enhances tumor uptake while reducing accumulation in normal tissues. Preclinical studies show that compared with other FAP ligands, this product exhibits rapid tumor targeting, higher tumor uptake, and superior pharmacokinetic properties.
Investigator-initiated trial (IIT) data in 35 patients with solid tumors (搜索), published in the Journal of Controlled Release, reported that 68Ga-GP01 — the active imaging component of GPN01530-2 (搜索) — detected more lesions and achieved higher tumor-to-background ratios than both 68Ga-FAPI-46 and 18F-FDG. The company reported zero adverse events within six hours post-injection across all patients and described rapid background clearance and sustained lesion uptake, with superior clinical image contrast and accuracy in detecting positive lesions compared with 18F-FDG.
Development and Manufacturing Capabilities
The early-stage research for the GPN01530-2 (搜索) program was fully conducted independently by the Group using its radiochemical labeling platform and animal molecular imaging platform at its Chengdu Radiopharmaceutical Base, enabling end-to-end completion of labeling process development and animal imaging studies. The program also leveraged a GMP-compliant production line to manufacture and release registration batches. This project represents the first proprietary product developed at the Chengdu Radiopharmaceutical Base to enter FDA-regulated clinical trials since the facility became operational.
The Chengdu Radiopharmaceutical R&D and Manufacturing Base, located in Wenjiang District, Chengdu City, Sichuan Province, passed final inspection in April 2025, received a Class A Radiation Safety License from China's Ministry of Ecology and Environment in May 2025, and officially commenced operations at the end of June 2025. As the world's first fully integrated radiopharmaceutical industrial platform, it covers the entire value chain — from isotope production and radiopharmaceutical R&D to clinical supply and commercialization.
Market Context and Pipeline
Cancer remains one of the leading causes of death worldwide. According to GLOBOCAN data, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022. By 2030, new cases are projected to approach 24 million annually, with deaths nearing 12 million.
The global radiopharmaceutical market grew from USD 5 billion in 2018 to USD 9.7 billion in 2024, reflecting a compound annual growth rate (CAGR) of 11.7%. It is forecast to reach USD 57.3 billion by 2035, with a CAGR of 17.5% from 2024 to 2035. In China, the market expanded from RMB 3.6 billion in 2018 to RMB 7.4 billion in 2024 (CAGR: 13.0%) and is expected to reach RMB 75.8 billion by 2035, representing a CAGR of 23.5% during 2024–2035.
Grand Pharma has built internationally leading R&D platforms for interventional oncology and RDCs. Guided by the concept of integrated diagnosis and therapy, the company currently has 16 innovative products in the clinical and regulatory pipeline, utilizing five radionuclides — 68Ga, 177Lu, 131I, 90Y, and 89Zr — and targeting seven cancer types, including hepatocellular carcinoma, prostate cancer, and brain cancer. To date, six innovative RDCs have been approved to conduct registrational clinical trials, with one having entered the NDA stage and three in Phase III clinical trials.
The next disclosed milestone for GPN01530-2 (搜索) is continued enrollment and data generation in the U.S. Phase I/II study. If development proceeds smoothly, GPN01530-2 could become a pivotal breakthrough in addressing current diagnostic challenges in solid tumors (搜索), potentially reshaping the diagnostic landscape and offering new hope to patients worldwide.